Patents by Inventor Olivier Vittecoq

Olivier Vittecoq has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR PREDICTING RHEUMATOID ARTHRITIS TREATMENT RESPONSE
    Publication number: 20160123992
    Abstract: The invention relates to methods and means for predicting rheumatoid arthritis treatment response.
    Type: Application
    Filed: June 10, 2014
    Publication date: May 5, 2016
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE DE ROUEN, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN
    Inventors: Olivier Vittecoq, Thierry Lequerre, Pascal Cosette, Olivier Boyer, Xavier Le Loët, Julie Hardouin, Antoine Obry
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20140086895
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of autoimmune diseases, especially rheumatoid arthritis. More particularly, the present invention relates to an a-enolase polypeptide for use in the prophylactic treatment of an autoimmune disease in a subject in need thereof.
    Type: Application
    Filed: May 10, 2012
    Publication date: March 27, 2014
    Applicants: Universite de Rouen, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Olivier Vittecoq, Céline Derambure, Thierry Lequerre, Olivier Boyer, Francois Tron, Xavier Le Loet, Daniêle Gilbert
  • METHOD OF TREATING RHEUMATOID ARTHRITIS
    Publication number: 20140072573
    Abstract: The invention relates to a method of treating rheumatoid arthritis in a patient comprising the steps of: a) providing a biological sample from a patient, b) measuring the level of soluble VE-cadherin in the biological sample obtained at step a); c) comparing said level of soluble VE-cadherin with a predetermined reference value, and if the level of soluble VE-cadherin measured at step b) is higher that the predetermined reference value, treating the patient until a basal level of soluble VE-cadherin is reached.
    Type: Application
    Filed: September 5, 2013
    Publication date: March 13, 2014
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Isabelle Vilgrain, Adama Sidibe, Tiphaine Mannic, Olivier Vittecoq, Xavier Le Loet
  • Method for predicting responsiveness to TNF? blocking agents
    Patent number: 7985549
    Abstract: The invention provides an in vitro method for predicting whether a patient would be responsive to a treatment with a TNF? blocking agent, which method comprises determining the expression level of eight genes in a biological sample of said patient, wherein said genes are EPS15, HLA-DPB1, AKAP9, RASGRP3, MTCBP-1, PTNP12, MRPL22 and RPS28. The invention further provides a DNA chip for performing such method.
    Type: Grant
    Filed: May 15, 2007
    Date of Patent: July 26, 2011
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Jean-Philippe Salier, Maryvonne Daveau, Anne-Christine Gauthier-Jauneau, Olivier Vittecoq, Xavier Le Loet, Alain Daragon, Othmane Mejjad, Thierry Lequerre
  • METHOD FOR PREDICTING THE RESPONSE TO A TREATMENT WITH ANAKINRA
    Publication number: 20110177966
    Abstract: The invention relates to a method for predicting the response of a patient to a treatment with anakinra, said method comprising a step of measuring the expression level of 7 genes in a biological sample of said patient, wherein said genes are GT-F2F2, CCT3, CROT, HNRPA3, ARL15, TMED5, and NRG3.
    Type: Application
    Filed: June 12, 2009
    Publication date: July 21, 2011
    Inventors: Xavier Le Loet, Olivier Vittecoq, Jean-Philippe Salier, Thierry Lequerre
  • Method for Predicting Responsiveness to TNF Alpha Blocking Agents
    Publication number: 20090252740
    Abstract: The invention provides an in vitro method for predicting whether a patient would be responsive to a treatment with a TNF? blocking agent, which method comprises determining the expression level of eight genes in a biological sample of said patient, wherein said genes are EPS15, HLA-DPB1, AKAP9, RASGRP3, MTCBP-1, PTNP12, MRPL22 and RPS28. The invention further provides a DNA chip for performing such method.
    Type: Application
    Filed: May 15, 2007
    Publication date: October 8, 2009
    Applicant: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Jean-Philippe Salier, Maryvonne Daveau, Anne-Christine Gauthier-Jauneau, Olivier Vittecoq, Xavier Le Loet, Alain Daragon, Othmane Mejjad, Thierry Lequerre